Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.
The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.
In a recent study posted to the medRxiv* preprint server, researchers illustrated cardiac findings in coronavirus disease 2019 (COVID-19)-recovered individuals more than a year after infection.
Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.
A study of one year outcomes in the largest cohort to date of Harmony transcatheter pulmonary valve (TPV) patients with congenital heart disease (CHD) and severe pulmonary regurgitation (PR) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions 2022 Scientific Sessions.
Children's Hospital Colorado (Children's Colorado) is the first hospital in the world to implant the newly FDA-approved G-Armor Stent. Although the stent is designed to be used in the smallest of patients, it was first implanted in a Colorado father of two.
Valve replacement heart surgery should be performed earlier than conventionally thought for people with aortic stenosis – according to new research from the University of East Anglia.
A study led by researchers at the National Institute for Health and Care Research Leicester Biomedical Research Centre has shown that a less invasive heart procedure for a common condition is just as effective as conventional open-heart surgery.
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association annual meeting in May.
Following a heart attack, the human body is incapable of repairing lost tissue due to the heart's inability to generate new muscle.
Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, "turn on" and become metastatic breast cancer.
The Canopy Cancer Collective, a national nonprofit organization that strives to fuel better treatments and outcomes for pancreatic cancer patients, has awarded The Tisch Cancer Institute at Mount Sinai a $500,000 grant to support continued innovation in its multidisciplinary treatment of pancreatic cancer.
The Mount Sinai Hospital has announced the completion of a full renovation of its children's Emergency Department (ED), and a newly redesigned area for walk-in, low acuity adult patients.
Most immunocompromised people with a blood cancer called multiple myeloma benefited from a third dose of COVID-19 vaccines, a promising sign after it was shown that two doses tended to not be sufficient for them.
Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who received a novel investigational device intended to repair the defective valve experienced significant improvements in blood flow through the heart and in quality of life at one year, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.
Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life and outcomes over an extended period of time, according to interim data from the EXPLORER-HCM extension study presented at the American College of Cardiology's 71st Annual Scientific Session.
A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.
Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.
Faculty from the Departments of Microbiology, Medicine Genetics and Genomic Sciences, and Pathology and Molecular Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai play key roles in a National Institutes of Health (NIH) program set up to provide a real-time risk assessment of variants of SARS-CoV-2, the virus that causes COVID-19. The program, called SARS-CoV-2 Assessment of Viral Evolution (SAVE) and described in a paper published March 31 in Nature, assesses how the variants might affect transmission, virulence, and resistance to both disease-induced (convalescent) and vaccine-induced immunity.
The dominant form of heart failure worldwide appears to be caused by a strong, bidirectional interaction between the body's response to metabolic stress and the immune system, according to a review article written by UT Southwestern researchers and colleagues.
A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.
In an unparalleled effort to deliver outstanding comprehensive care and to employ revolutionary approaches to novel therapeutics around the skin condition alopecia areata, the Mount Sinai Health System has launched the Alopecia Areata Center of Excellence.